3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Conditions
Ovarian Neoplasms
4
Endometrial Neoplasms
3
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
3
sargramostim
2
tislelizumab
1
spartalizumab
1
milademetan
1
devimistat
1
dehydroftorafur
1
bemarituzumab
1
aldesleukin
1
Specimen Handling
1
Magnetic Resonance Spectroscopy
1
Interleukin-2
1
IFL protocol
1
Hydroxychloroquine
1
Gemcitabine
1
Fluorouracil
1
Cetuximab
1
Carboplatin
1
Bevacizumab
1
AZD5305
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
AZD5305
×
Gynecologic
×
Clear all
NCT05797168
2026-06-03
FONTANA
AstraZeneca
Phase 1/2
Recruiting
506 enrolled